Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Normal or Varying Degrees of Impaired Renal Function

Drugs in R and D

Volumn 14, Issue 4, 2014, Pages 273-282

  Mayer, Michael ^a   Nudurupati, Sai ^a   Peng, Xuejun ^a   Marcinak, John ^a  

^a Takeda Development Center Americas Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FASIGLIFAM; ANTIDIABETIC AGENT; BENZOFURAN DERIVATIVE; SULFONE; TAK-875;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOGLYCEMIA; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; NAUSEA; ORAL CLEARANCE; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; RHINOPHARYNGITIS; SEVERE RENAL IMPAIRMENT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CLINICAL TRIAL; KIDNEY DISEASES; MIDDLE AGED; URINE;

ADULT; AGED; BENZOFURANS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; MALE; MIDDLE AGED; RENAL DIALYSIS; SULFONES;

EID: 84919462540     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-014-0066-4     Document Type: Article

References (22)

1. IDF Diabetes Atlas. International Diabetes Federation. http://www.idf.org/diabetesatlas/5e/the-global-burden. Accessed 30 May 2014.
2. National Diabetes Statistics, 2011. National Institutes of Health. National Diabetes Information Clearinghouse (NDIC). NIH Publication No. 11-3892. http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm. Accessed 5 June 2014.
3. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011;123:133–43.
4. Middleton RJ, Foley RN, Hegarty J, Cheung CM, McElduff P, Gibson JM, et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant. 2006;21:88–92.
5. Rodriguez-Poncelas A, Garre-Olmo J, Franch-Nadal J, Diez-Espino J, Mundet-Tuduri X, Barrot-De la Puente J, et al. Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study. BMC Nephrol. 2013;14:46.
6. Avogaro A, Schernthaner G. Achieving glycemic control in patients with type 2 diabetes and renal impairment. Acta Diabetol. 2013;50(3):283–91.
7. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med. 1998;15:297–303.
8. ® (metformin hydrochloride) tablets: full prescribing information. Princeton: Bristol-Myers Squibb Company; 2009.
9. ® (sitagliptin) tablets: full prescribing information. Whitehouse Station: Merck & Co., Inc.; 2013.
10. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60:850–86.
11. Negoro N, Sasaki S, Mikami S, Ito M, Suzuki M, Tsujihata Y, et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Ltrs. 2010;1:290–4.
12. Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther. 2011;339:228–37.
13. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes. 2008;57(9):2280–7.
14. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther. 2012;340:483–9.
15. Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care. 2013;36:245–50.
16. Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:271–8.
17. Leifke E, Naik H, Wu J, Viswanathan P, Demanno D, Kipnes M, et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther. 2012;92:29–39.
18. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:1403–11.
19. Naik H, Vakilynejad M, Wu J, Viswanathan P, Dote N, Higuchi T, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol. 2012;52:1007–16.
20. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065–74.
21. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.
22. American Diabetes Association. Statistics about diabetes. Data from the 2011 National Diabetes Fact Sheet (released January 26, 2011). http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed 30 May 2014.